Caplin Point gets EIR for its plant in Tamil Nadu

Capling Point Laboratories has announced receiving Establishment Inspection Report from the US health regulator for its Gummidopoondi facility in Chennai.

In a filing to BSE and NSE, it said, “Caplin Point has received the Establishment Inspection Report (EIR) from USFDA (The United States Food and Drug Administration) for inspection carried out during Oct 21-27, 2016, at its sterile injectable plant at Gummidopoondi in Tamil Nadu.”

According to Caplin Point Laboratories Chairman C C Paarthipan, “this will pave the way for our entry into the largest pharma market in the world.”

The facility, capable of manufacturing liquid injectables in vials, ampoules, lyophilized vials and ophthalmic dosages, is approved by EU-GMP and ANVISA-Brasil.

Image credit:

Research Desk

Next Post

India set to become 3rd largest solar power market in 2017

Wed May 10 , 2017
India Solar Handbook 2017 by Bridge to India has said India will become the third biggest solar market globally in 2017. The handbook by the consulting and knowledge service provider in the clean technology market has said with 8.8 gw (giga watt) of projected capacity addition — a growth of […]
Mercom India


Blog Stats